biostudies-literatureUnknown127(8)Musacchio L<h4>Background</h4>Low-grade serous ovarian and peritoneal cancer (LGSC) is a rare disease and few data on the clinical and genomic landscape have been published.<h4>Methods</h4>A retrospective analysis of patients diagnosed with LGSC between 1996 and 2019 was conducted in MITO centers. Objective Response Rate (ORR) to treatments, progression-free survival (PFS) and overall survival (OS) were assessed. Additionally, the tumor molecular profile of 56 patients was evaluated using the Next Generation Sequencing (NGS) FoundationOne CDX (Foundation Medicine®).<h4>Results</h4>A total of 128 patients with complete clinical data and pathologically confirmed diagnosis of LGSC were identified. ORR to first and subsequent therapies were 23.7% and 33.7%, respectively. PFS was 43.9 months (95% CI:32.4-British journal of cancer1479-1486https://www.ebi.ac.uk/biostudies/studies/S-EPMC9553882biostudies-literatureClinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).PMC9553882Russo DPerrone FDel Vecchio VScalone SMusacchio LCasanova CZannoni GFRaspagliesi FPriolo DTuninetti VScambia GLosito NSValabrega GFerrau FPisano CSpina ACanzonieri VDucceschi MPignata SSalutari VLorusso DGhizzoni VCormio GGreggi SBartoletti MDel Sesto MLoizzi VCalifano DArenare LfalseClinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).<h4>Background</h4>Low-grade serous ovarian and peritoneal cancer (LGSC) is a rare disease and few data on the clinical and genomic landscape have been published.<h4>Methods</h4>A retrospective analysis of patients diagnosed with LGSC between 1996 and 2019 was conducted in MITO centers. Objective Response Rate (ORR) to treatments, progression-free survival (PFS) and overall survival (OS) were assessed. Additionally, the tumor molecular profile of 56 patients was evaluated using the Next Generation Sequencing (NGS) FoundationOne CDX (Foundation Medicine®).<h4>Results</h4>A total of 128 patients with complete clinical data and pathologically confirmed diagnosis of LGSC were identified. ORR to first and subsequent therapies were 23.7% and 33.7%, respectively. PFS was 43.9 months (95% CI:32.4-2022-01-01T00:00:00Z2022 Nov2026-07-14T23:32:45.94Z2025-04-04T20:07:27.508ZS-EPMC95538823586914310.1038/s41416-022-01897-1